Pfizer Independent Grants for Learning & Change Request for Proposals (RFP): Shared Management of Psoriatic Arthritis

Funding Agency:
Pfizer Inc.

The mission of Pfizer Independent Grants for Learning & Change (IGLC) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. “Independent” means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

The intent of this document is to encourage organizations with a focus in healthcare professional education and/or quality improvement to submit a letter of intent (LOI) in response to a Request for Proposal (RFP) that is related to education in a specific disease state, therapeutic area, or broader area of educational need. The RFP model is a two-stage process. Stage 1 is the submission of the LOI. After review of the LOI, you may be invited to submit your Full Grant Proposal. Stage 2 is the submission of the Full Grant Proposal. 

Evidence indicates that many patients with Psoriatic Arthritis (PsA) remain undiagnosed, and those who have been diagnosed are not receiving optimal care.1 It is our intent to support projects that focus on the coordinated management and identification of patients with psoriatic arthritis (PsA) by both rheumatology and dermatology healthcare professionals. 

Patients with Psoriatic Arthritis experience symptoms that involve both the skin and the joints, impacting their quality of life.2Given the nature of the disease, patients may seek care from both dermatologists and rheumatologists, as the disease progresses through periods of flare and remission. A collaborative approach to treatment by a combined team of rheumatology and dermatology clinicians allows for a unique blend of expertise and provides the opportunity for comprehensive care for the PsA patient.3

It is expected that projects will be evidence-based and the proposed evaluation will follow generally accepted scientific principles. During review the intended outcome of the project is given careful consideration and, if appropriate based on the project goal, projects with the maximum likelihood to directly impact patient care will be given high priority.

LOI due date: June 23, 2017

Agency Website

Eligibility Requirements

The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations; government agencies; and other entities with a mission related to healthcare improvement. 



Amount Description

Individual projects requesting up to $350,000 will be considered. The total available budget related to this RFP is $1,000,000.

Funding Type





Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

June 23, 2017